Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Time to protection and adherence requirements of raltegravir with or without lamivudine for HIV prevention
2016-000437-43Phase 4Completed
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of raltegravir and lamivudine in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Guy's and St Thomas' NHS Foundation Trust. Primary endpoint: Mucosal drug levels for ex vivo HIV protection. Started Mar 2017; status: completed.
02
Drugs
raltegravirlamivudine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2016-000437-43.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000437-43.